Direct compression of simvastatin into immediate-release tablet cores is typically performed by pre-blending the API with a protective antioxidant–acidulant system before the main bulking excipients are added, because simvastatin is a BCS class II compound with low aqueous solubility and a lactone ring that is vulnerable to hydrolytic opening under elevated moisture and alkaline pH. The compendial terminal product covers 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg strengths; for a core mass of 160 mg to 400 mg, the simvastatin addition ratio is 1.25% w/w to 20% w/w, and the low-dose 5 mg core is the most sensitive to segregation and overblending on multi-purpose direct-compression lines. Compendial release for commercial batches includes USP <711> dissolution testing in a surfactant-enriched aqueous medium with apparatus II at 50 rpm, USP <905> uniformity of dosage units with acceptance value not more than 15.0, and FDA 21 CFR 210/211 current good manufacturing practice requirements; where EU market access is required, Ph. Eur. 2.9.40 uniformity of dosage units and the applicable Ph. Eur. simvastatin tablet monograph apply. Stability studies are run according to ICH Q1A(R2) with long-term storage at 25 °C/60% RH and accelerated testing at 40 °C/75% RH. Downstream processing begins with a passivated pre-blend containing butylated hydroxyanisole, ascorbic acid, and citric acid monohydrate, screened through a 30 mesh to 40 mesh sieve, then blended with lactose monohydrate, microcrystalline cellulose, and partially pregelatinized starch in a bin blender or V-blender. Blend homogeneity sampling is stratified because simvastatin fines migrate under extended rotation and create content-uniformity drift before compression; changeover between low and high strengths on shared tooling also requires swab recovery data under FDA 21 CFR 211.67 to prevent cross-contamination of 5 mg and 80 mg campaigns. Croscarmellose sodium is added before final lubrication with magnesium stearate at 0.25% w/w to 0.5% w/w, and the lubricated blend is compressed on a high-speed rotary tablet press with precompression rollers; compression force is adjusted to produce cores of 7 kp to 15 kp hardness while maintaining disintegration below 15 min. API particle-size distribution is controlled by laser diffraction per USP <429> or ISO 13320:2020 because dissolution is sensitive to the fine fraction. The terminal product is a film-coated immediate-release simvastatin tablet, with the coating applied to reduce light and moisture exposure to the lactone ring; the coating suspension must be low-moisture or non-aqueous to avoid surface hydrolysis during pan application.

What Limits Blend Uniformity and Layer Integrity in Ezetimibe/Simvastatin Fixed-Dose Combination Cores?

In fixed-dose combination development, the primary process conflict is not drug–drug incompatibility but the different bulk densities and flow properties of ezetimibe and simvastatin, which can drive layer segregation and weight-control drift on bilayer presses. The market-relevant unit strengths pair 10 mg ezetimibe with 10 mg, 20 mg, 40 mg, or 80 mg simvastatin; with a total core mass of 300 mg to 500 mg, the simvastatin addition ratio ranges from 2.0% w/w to 26.7% w/w. Compendial release is governed by the applicable USP combination tablet monograph, USP <711> dissolution, and USP <905> uniformity of dosage units, while cleaning validation between strengths follows FDA 21 CFR 211.67 and cross-contact acceptance limits must be justified by permitted-daily-exposure or toxicological data. Downstream processing for bilayer cores uses a rotary bilayer press with two separately controlled feed frames; the ezetimibe-containing first layer is tamped at a low force, typically 1 kN to 5 kN, before the simvastatin-containing second layer is filled and final compression is applied. Layer hardness and dedusting after first-layer tamping are critical because micro-particulate carryover between the two feed frames can cause assay cross-contamination and out-of-specification uniformity. The simvastatin layer is preferably produced by roller compaction or dry granulation rather than wet granulation because aqueous exposure accelerates lactone hydrolysis and reduces assay stability. A 2 mm oscillating granulator screen is used to de-agglomerate the roller-compacted ribbons, and the granulation is compressed with an excipient matrix containing lactose, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The terminal product is a film-coated ezetimibe/simvastatin tablet in 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg strengths.

Because the uncoated tablet route introduces a film-coating step that may expose simvastatin to waterborne coating stress, hard capsule filling is used as an alternative dry-finish route for strengths from 5 mg to 40 mg. Hard capsule formulations are filled at total fill weights of 100 mg to 400 mg; the resulting API addition ratio spans 1.25% w/w to 40% w/w, with the low-dose 5 mg capsule requiring geometric dilution and a sacrificial blend step to achieve uniform distribution before filling. Release testing is performed against USP <711> dissolution and USP <905> uniformity of dosage units, and capsule shells must meet the applicable USP requirements for disintegration and moisture protection. The simvastatin API is pre-blended with butylated hydroxyanisole and citric acid monohydrate in a low-shear mixer, then passed through a 40 mesh screen. The pre-blend is added to a dry diluent base of lactose monohydrate or mannitol, microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide; final magnesium stearate lubrication is kept below 0.5% w/w to prevent hydrophobic dissolution delay. Filling is performed on a dosator-type or tamping-pin encapsulator with volumetric fill control; machine speed and vacuum are limited to prevent powder compaction that can alter capsule disintegration. Capsule shells are low-moisture HPMC or hard gelatin; the terminal product is a hard capsule containing 5 mg, 10 mg, 20 mg, or 40 mg simvastatin.

When Pediatric or Dysphagic Dose Flexibility Requires Simvastatin Oral Granules for Suspension

When pediatric or dysphagic patients require dose flexibility, simvastatin is formatted as granules or dispersible powder for oral suspension rather than as a split tablet. The unit strength per sachet is 5 mg, 10 mg, 20 mg, or 40 mg; with a sachet fill mass of 1 g to 2 g, the API addition ratio is 0.25% w/w to 4.0% w/w. When reconstituted to 5 mL or 10 mL, the resulting suspension commonly carries labelled concentrations of 20 mg/5 mL or 40 mg/5 mL; published harmonized formula data for some suspension configurations remains limited, so site-specific stability must be generated to justify a beyond-use date. Release testing on granules and reconstituted suspension includes USP <905> uniformity of dosage units, USP <711> dissolution with surfactant-enriched aqueous medium, and microbial enumeration limits for non-sterile oral liquids under USP <61> and USP <62>. Downstream production uses low-shear mixing rather than high-shear granulation to minimize heat input; the API is pre-blended with butylated hydroxyanisole, citric acid monohydrate, and ascorbic acid, then combined with sucrose or mannitol, xanthan gum or carboxymethylcellulose sodium, and a low-moisture binder. The blend is dry granulated by roller compaction or slugging, screened through a 16 mesh to 20 mesh screen, and packed in unit-dose sachets with aluminum foil or multi-layer barrier film. The terminal product is an oral granule or powder for suspension in a single-dose sachet, intended for dispersion in water immediately before administration.

Parenteral Nanosuspension Processing Without a Harmonized Finished-Product Monograph

Parenteral administration of simvastatin does not correspond to a harmonized monographed finished-product dosage form, and industrial activity is concentrated in clinical trial parenterals, local delivery systems, and preclinical models. The API for injectable development must meet USP <85> bacterial endotoxins, USP <788> particulate matter for injections, USP <71> sterility tests, and the sterile manufacturing requirements of FDA 21 CFR 210/211; because simvastatin is water-insoluble and susceptible to lactone hydrolysis, the terminal product is usually a nanosuspension or lyophilized formulation rather than a simple aqueous solution. No pharmacopoeial fixed addition ratio exists; published investigational protocols have used parenteral concentrations in the low milligram-per-millilitre range, and total doses are determined by clinical or preclinical protocol rather than by monograph. Where a specific dose-strength is absent from public regulatory filings, the absence should be stated rather than bridged with unverifiable figures. Downstream processing for a parenteral nanosuspension typically involves high-pressure homogenization or wet media milling of simvastatin with stabilizers such as poloxamer 188, lecithin, or vitamin E TPGS; the particle-size distribution is characterized by laser diffraction per ISO 13320:2020 or USP <429>, with the target median particle size controlled to the submicron range. Sterilization is performed by terminal filtration if the particle size is compatible with a 0.22 µm filter, or by aseptic processing when the particulate dispersion cannot be filtered; lyophilization with mannitol or trehalose is used to reduce aqueous exposure. The terminal product is an investigational injectable nanosuspension or lyophilized cake for reconstitution, not a standard commercial monograph product.